Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces First Quarter 2018 Financial Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including…
Read this Press Release: Poxel Announces First Quarter 2018 Financial UpdatePoxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases,…
Read this Press Release: Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences ConferencePoxel Provides Business Update and Reports Results for Full Year 2017
Signed two strategic partnership agreements for Imeglimin for global rights with potential value of up to approximately $925 million plus royalties on net sales …
Read this Press Release: Poxel Provides Business Update and Reports Results for Full Year 2017
Upcoming Events
American Diabetes Association Meeting
